期刊文献+

食管鳞癌中细胞周期素A的表达对紫杉醇疗效的影响 被引量:2

Effects of cyclin A expression on efficacy of treating esophageal squamous cell carcinoma with paclitaxel
原文传递
导出
摘要 目的观察化疗前食管鳞癌组织中细胞周期素A的表达对紫杉醇化疗疗效的影响。方法采用免疫组化法检查48例初治食管鳞癌组织中细胞周期素A的表达。患者接受含紫杉醇为主的方案化疗两周期后评价近期疗效,随访3年生存期。结果细胞周期素A表达阳性患者化疗有效率54.8%,高于表达阴性患者的23.5%(P<0.05)。肿瘤分期、分化程度、细胞周期素A的表达是影响食管鳞癌预后的独立因素。结论细胞周期素A表达阳性的食管鳞癌患者对紫杉醇有较高的敏感性,可以作为预测紫杉醇疗效的参考指标。 Objective To evaluate the effects of cyclin A expression on efficacy of treating esophageal squamous cell carcinoma(ESCC) with paclitaxel. Methods Expression of cyclin A was detected using immunohistochemical MaxVision method in 48 patients before chemotherapy,who were newly diagnosed with ESCC and received two cycles of paclitaxel-based chemotherapy.Short-term efficacy was evaluated and 3-year survival was followed up.Results The effectiveness rate was higher in patients with cyclin A positive than that with negative(54.8% vs. 23.5%) (P0.05). The univariate and the Cox multivariate analysis revealed that the clinical pathological stage,degree of differentiation and cyclin A expression were the independent factors to influence the prognosis in patients with ESCC. Conclusion ESCC patients with positive cyclin A expression have more sensitivity to paclitaxel treatment,suggesting that cyclin A expression may be taken as a marker to predict the efficacy of paclitaxel.
出处 《江苏医药》 CAS CSCD 北大核心 2011年第3期277-280,F0003,共5页 Jiangsu Medical Journal
基金 2009年度江苏省"333"工程科研资助项目[苏人才办(2009)24号]
关键词 细胞周期素A 紫杉醇 食管鳞癌 Cyclin A Paclitaxel Esophageal squamous cell carcinoma
  • 相关文献

参考文献6

二级参考文献57

共引文献28

同被引文献16

  • 1邓薇,沈琳.胃癌靶向药物治疗进展[J].中国医学前沿杂志(电子版),2013,5(1):29-41. 被引量:8
  • 2庞蓓蓓,周毅,龙浩成,陶德定,胡俊波,龚建平.胃肠道肿瘤细胞周期素A的表达及其与化疗药物敏感性的关系[J].华中科技大学学报(医学版),2007,36(4):521-524. 被引量:2
  • 3张爱群,付红霞,孙富国,李金生,周爱玲,王学民,柯小宁.Cyclin A与P21蛋白在子宫腺肌病中的表达及临床意义[J].河北医药,2007,29(11):1163-1165. 被引量:5
  • 4Rocha - Lima CM, Soares HP, Raez LE, et al. EGFR targeting of solid tumorst[ J ]. Cancer Control,2007,14 ( 3 ) : 295.
  • 5Wolff AC, Hammond ME, Schwartz JN, et ai. American society of clinical oncology/college of American pathologists guideline recom- mendations for human epidermal growth factor receptor 2 testing in breast cancer[ J ]. J Clin Onco1,2007,25 ( 1 ) : 118 - 145.
  • 6Liakakos T, Fatourou E, Ziogas D. Targeting VEGF, EGFR, and other interacting pathways for gastric cancer promises and reality [ J ]. Ann Surg Oncol,2008,15 ( 10 ) :2981 - 2982.
  • 7Lieto E, Ferraraccio F, Orditura M. Expression of vascular endo- thelial growth factor(VEGF) and epidermal growth factor receptor(EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients[ J ]. Ann Surg Oncol,2008,15 (1) :69 -79.
  • 8Paterlini P, Subervillc AM, Zindy F, et al. Cyclin A expression in human hematological malignancies : a new marker of cell prolifera- tion [ J ]. Cancer Ras, 1993,53:235 - 238.
  • 9BostrSm P, Sderstrm M, Palokangas T, et al. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade andother prognostic factors[ J]. BMC Res Notes,2009,2 ( 1 ) : 140 - 148.
  • 10Yoom BS, Kim YT, Kim S, et al. Prognostic value of nuclear DNA quantification and cyclin A expression in epithelial ovarian carci- noma [ J ]. Eur J Obstet Gynecol Reprod Biol, 2008,136 ( 1 ) : 110 -115.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部